Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [1] Pharmacy care and adherence to primary and secondary prevention cardiovascular medication: a systematic review of studies
    Jalal, Zahraa S.
    Smith, Felicity
    Taylor, David
    Patel, Hemant
    Finlay, Katherine
    Antoniou, Sotiris
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2014, 21 (04): : 238 - 244
  • [2] Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review
    Banerjee, Amitava
    Khandelwal, Shweta
    Nambiar, Lavanya
    Saxena, Malvika
    Peck, Victoria
    Moniruzzaman, Mohammed
    Faria Neto, Jose Rocha
    Quinto, Katherine Curi
    Smyth, Andrew
    Leong, Darryl
    Werba, Jose Pablo
    OPEN HEART, 2016, 3 (02):
  • [3] Improving adherence to medication for secondary cardiovascular disease prevention
    Keenan, Jan
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 : 29 - 35
  • [4] The polypill in the primary prevention of cardiovascular disease
    Wald, David S.
    Wald, Nicholas J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (01) : 29 - 35
  • [5] A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke
    Carey, Katherine M.
    Comee, Morgan R.
    Donovan, Jennifer L.
    Kanaan, Abir
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (05) : 688 - 695
  • [6] Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease
    Hope, Holly F.
    Binkley, George M.
    Fenton, Sally
    Kitas, George D.
    Verstappen, Suzanne M. M.
    Symmons, Deborah P. M.
    PLOS ONE, 2019, 14 (01):
  • [7] The polypill and cardiovascular disease - May be appropriate for secondary, but perhaps notfor primary prevention
    Fahey, T
    Brindle, P
    Ebrahim, S
    BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7499): : 1035 - 1036
  • [8] Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
    Jahangiri, Reza
    Rezapour, Aziz
    Malekzadeh, Reza
    Olyaeemanesh, Alireza
    Roshandel, Gholamreza
    Motevalian, Seyed Abbas
    PLOS ONE, 2022, 17 (07):
  • [9] Improving medication adherence in patients with cardiovascular disease: a systematic review
    Fuller, Rosemary Hines
    Perel, Pablo
    Navarro-Ruan, Tamara
    Nieuwlaat, Roby
    Haynes, Robert Brian
    Huffman, Mark D.
    HEART, 2018, 104 (15) : 1238 - 1243
  • [10] Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
    Zhu, Ling -Ling
    Zhou, Quan
    VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 659 - 660